What’s likely to move the market in the next trading session

What’s likely to move the market in the next trading session

U.S. Federal Reserve Chair Jerome Powell speaks at a news conference on interest rates, the economy and monetary policy actions on June 15, 2022. Olivier Douliery- | Afp | Getty Images Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and last look at today. Sign up for … Read more

Medicare releases prices for first 10 drugs subject to negotiations

Medicare releases prices for first 10 drugs subject to negotiations

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services building in Washington, D.C., on Oct. 6, 2022. Anna Moneymaker | Getty Images The Biden administration on Thursday will release prices for the first 10 prescription drugs that were subject to landmark negotiations between drugmakers and … Read more

Drugmakers on new negotiated prices with Medicare

Drugmakers on new negotiated prices with Medicare

President Joe Biden speaks during an event at the National Institutes of Health in Bethesda, Maryland, Dec. 14, 2023. Chris Kleponis | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The first round of Medicare drug price negotiations has come … Read more

Humira sales are falling, but AbbVie has successors

Humira sales are falling, but AbbVie has successors

Humira, the injectable rheumatoid arthritis treatment is pictured in a pharmacy in Cambridge, Massachusetts. JB Reed | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie‘s Humira are plummeting as the once-top-selling drug fights competition from cheaper … Read more

AbbVie taps Robert Michael as CEO, succeeding Richard Gonzalez

AbbVie taps Robert Michael as CEO, succeeding Richard Gonzalez

Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. Dado Ruvic | Reuters AbbVie on Tuesday said longtime executive Robert Michael will become the company’s new CEO, replacing Richard Gonzalez.  Michael, who is AbbVie’s president and chief operating officer, will become the company’s second-ever CEO … Read more

Varda drug spacecraft gets FAA approval to return

Varda drug spacecraft gets FAA approval to return

Varda’s first manufacturing satellite and reentry vehicle attached to a Rocket Lab Photon bus. Rocket Lab Space startup Varda received long-awaited approval from the Federal Aviation Administration to bring its first spacecraft back to earth after a stint manufacturing drugs in space. Varda’s small W-Series 1 capsule, or W-1, has been stuck in orbit since … Read more

Big pharma Merck, Bristol Myers, J&J prepare to lose revenue

Big pharma Merck, Bristol Myers, J&J prepare to lose revenue

The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium.  NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a … Read more

J&J to acquire Ambrx Biopharma, a cancer drug developer, for $2B

J&J to acquire Ambrx Biopharma, a cancer drug developer, for B

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment. … Read more

Cramer names biopharma companies as industry mergers start to accrue

Cramer names biopharma companies as industry mergers start to accrue

CNBC’s Jim Cramer on Friday pointed out the number of biopharma mergers and acquisitions that have closed or been announced over the last few months. He told investors to keep an eye on these moves in advance of the JPMorgan health care conference next week. “I know that drug companies are tough to own in … Read more

AbbVie to acquire Cerevel Therapeutics for $8.7 billion

AbbVie to acquire Cerevel Therapeutics for .7 billion

AbbVie on Wednesday said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion.  Under the terms of the deal, AbbVie will pay $45 per share for Cerevel. AbbVie said it expects to complete the acquisition in the middle of 2024.  Shares of Cerevel jumped 16% after the close Wednesday to nearly $43 per … Read more